Pharmacy Legislative Update 2025                          

Jonathan Hickman, PharmD, Medical Executive Director, Genentech

Upon completion of this activity, pharmacists will be able to: Discuss the recent changes of the 2025 Legislative Session and its effect on the profession of pharmacy; Describe the steps pharmacy must complete to maintain compliance with current Florida laws; Provide resources the profession may access to remain up to date with current Florida laws.

UAN: 0675-0000-25-022-H03-P

Upon completion of this activity, technicians will be able to: Discuss the recent changes of the 2025 Legislative Session and its effect on the profession of pharmacy; Describe the steps pharmacy must complete to maintain compliance with current Florida laws; Provide resources the profession may access to remain up to date with current Florida laws.

UAN: 0675-0000-25-022-H03-T

Sterile Compounding: The Road to Compliance                                           

Gillian Staiko, RPh, CISCI, Regulatory Compliance Director, Hims and Hers

Upon completion of this activity, pharmacists will be able to: Describe the importance of USP; Discuss the requirements of USP 797 and 800; Identify the FDA Guidance Documents that apply to 503a pharmacies.
UAN: 0675-0000-25-023-H07-P

Upon completion of this activity, technicians will be able to: Describe the importance of USP; Discuss the requirements of USP 797 and 800; Identify the FDA Guidance Documents that apply to 503a pharmacies.

UAN: 0675-0000-25-023-H07-T

Anatomy of a Pharmacy Fraud Case              

Ronald Chapman II, Founder and Manager, Safe Harbor Group

Upon completion of this activity, pharmacists will be able to: Identify top compliance risks commonly faced by pharmacies and other healthcare entities; Evaluate how their current compliance practices align with regulatory expectations; Apply practical strategies to mitigate compliance risk and integrate a proactive compliance culture.

UAN: 0675-0000-25-024-H03-P

Upon completion of this activity, technicians will be able to: Identify top compliance risks commonly faced by pharmacies and other healthcare entities; Evaluate how their current compliance practices align with regulatory expectations; Apply practical strategies to mitigate compliance risk and integrate a proactive compliance culture.

UAN: 0675-0000-25-024-H03-T

Florida Board of Pharmacy 2024-2025 Legislation and Rule Update   

Chris Bierdlam, Of Counsel, Grossman Roopnarine & Bayó, LLC.

Upon completion of this activity, pharmacists will be able to:  Identify recent changes to the Florida statutes affecting the practice of pharmacy and the rule provisions being amended by the Board of Pharmacy to implement those changes; Explain how these new statutes and rules will impact the everyday practice of pharmacy in Florida including licensure implications, compounding, dispensing, recordkeeping, and patient counseling; Evaluate the implications that these changes will have on the everyday practice life of practicing pharmacists; Describe the updates related to pharmacy technician supervision and the current status of the Board’s proposed expansion of pharmacy technician supervision; Apply current legal requirements to real-world pharmacy scenarios to ensure compliance; Recognize the role of pharmacists in collaborative practice and test and treat settings and how they can enhance public health through policy engagement; Summarize anticipated future legislative trends and their potential impact on pharmacy practice.

UAN: 0675-0000-25-025-H03-P

Upon completion of this activity, technicians will be able to: Identify recent changes to the Florida statutes affecting the practice of pharmacy; Explain how these new statutes and rules will impact the everyday practice of pharmacy in Florida; Describe the updates related to pharmacy technician supervision and the current status of the Board’s proposed expansion of pharmacy technician supervision; Apply current legal requirements to real-world pharmacy scenarios to ensure compliance.

UAN: 0675-0000-25-025-H03-T

CMS Medication Updates and Regulations in LTC Settings

Lynn D’Avico, PharmD, CPH, Clinical Education Coordinator, Polaris Pharmacy

Upon completion of this activity, pharmacists will be able to: Update guidance/language for CMS regulatory changes; Discuss changes to F-tags and its effect on survey process; Discuss guidance changes to: Fentanyl Patch disposal, Antibiotic Stewardship requirements, CMS regulations on psychotropic medications, and guidance on Unnecessary Medications in LTC settings; Describe trauma and its effects on residents and staff.

UAN: 0675-0000-25-027-H03-P

Upon completion of this activity, technicians will be able to: Review language for CMS regulatory changes; Discuss changes to F-tags and its effect on survey process; Discuss guidance changes to: Fentanyl Patch disposal, Antibiotic Stewardship requirements, CMS regulations on psychotropic medications, and guidance on Unnecessary Medications in LTC settings; Describe trauma and its effects on residents and staff.

UAN: 0675-0000-25-027-H03-T

From COVID to AI in Telepharmacy                                                      

Christopher B. Sullivan, PhD, President, Image Research LLC

Upon completion of this activity, pharmacists will be able to: Explain the basic applications of telepharmacy technology as they exist today; Recognize the innovations in telepharmacy services due to the COVID-19 pandemic; Describe the background of AI as it developed out of earlier systems such as IBM’s Watson, Google’s search engine and Apple’s SIRI algorithms; Identify the difference between Traditional AI, which can learn from data and make predictions based on the date, and Generative AI, which can create new formulations from existing data; Discuss future telepharmacy opportunities and challenges created by AI.

UAN:0675-0000-25-028-H04-P

Upon completion of this activity, technicians will be able to: Explain the basic applications of telepharmacy technology as they exist today; Recognize the innovations in telepharmacy services due to the COVID-19 pandemic; Describe the background of AI as it developed out of earlier systems such as IBM’s Watson, Google’s search engine and Apple’s SIRI algorithms; Identify the difference between Traditional AI, which can learn from data and make predictions based on the date, and Generative AI, which can create new formulations from existing data; Discuss future telepharmacy opportunities and challenges created by AI.

UAN: 0675-0000-25-028-H04-T

DSCSA: “Take Two” for Title II

Heather Fuller, PharmD, M.B.A., M.S., AdventHealth, Corporate Pharmacy Procurement Manager,

Upon completion of this activity, pharmacists will be able to: Discuss the history of DSCSA and where we are now; Develop a solid understanding of the DSCSA requirements for Dispensers; Review case scenarios and ways to operationalize the requirements.

UAN: 0675-0000-25-029-H03-P

Upon completion of this activity, technicians will be able to: Discuss the history of DSCSA and where we are now; Develop a solid understanding of the DSCSA requirements for Dispensers; Review case scenarios and ways to operationalize the requirements.

UAN: 0675-0000-25-029-H03-T

Florida Pharmacy Law & the Disciplinary Process                   

Edwin Bayo, Founding Partner, Grossman, Roopnarine & Bayó, LLC.

Upon completion of this activity, pharmacists will be able to: Describe the life cycle of a Department of Health/Board of Pharmacy investigation from complaint intake through probable cause review, administrative processes, board action, and remedies; Compare the due process rights of pharmacists and permit holders at each stage of the disciplinary process, including notice requirements, access to the investigative file, and available hearing options; Identify the statutory and rule-based grounds for discipline under Chapters 456, 465, 499 & 893, Florida Statutes, and Rule Chapter 64B16, F.A.C., with emphasis on misfills, inspection deficiencies, impairment, and criminal convictions; Formulate proactive compliance strategies—including record-keeping, staff training, and self-reporting—that reduce the risk of disciplinary action and support mitigation if violations occur; Explain the role and obligations of key pharmacy leaders (Prescription Department Manager/PIC and designated representatives) in maintaining permit compliance and responding to DOH inquiries.

UAN: 0675-0000-25-030-H03-P

Upon completion of this activity, technicians will be able to: Describe the life cycle of a Department of Health/Board of Pharmacy investigation from complaint intake through probable cause review, administrative processes, board action, and remedies; Identify the due process rights at each stage of the disciplinary process; Explain the role and obligations of key pharmacy leaders (Prescription Department Manager/PIC and designated representatives) in maintaining permit compliance and responding to DOH inquiries.

UAN: 0675-0000-25-030-H03-T